SlideShare une entreprise Scribd logo

Pharmacoeconomics1

•Télécharger en tant que PPT, PDF•
•
J
jinender16
1  sur  27
PHARMACOECONOMICS ,[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Preview
PHARMACOECONOMICS RESEARCH ,[object Object],[object Object],[object Object],[object Object]
VALUE Health Outcome Cost
USE OF PHARMACOECONOMIC RESEARCH ,[object Object],[object Object],[object Object],[object Object],[object Object]
NEEDS TO MONITOR VALUE OF PHARMACEUTICALS ,[object Object],[object Object],[object Object],[object Object]
TYPES OF PHARMACOECONOMIC EVALUATION ,[object Object],[object Object],[object Object],[object Object],[object Object]
COMPARING PHARMACOECONOMIC METHODOLOGIES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
STEPS FOR CONDUCTING A PHARMACOECONOMIC EVALUATION ,[object Object],[object Object],[object Object],[object Object]
DEFINE THE PROBLEM AND STATE THE OBJECTIVE ,[object Object],[object Object]
PERSPECTIVE ,[object Object],[object Object],[object Object],[object Object]
PERSPECTIVE ,[object Object]
IDENTIFYING ALTERNATIVE INTERVENTIONS ,[object Object]
IDENTIFYING ALTERNATIVE INTERVENTIONS ,[object Object]
IDENTIFY AND MEASURE OUTCOMES OF EACH ALTERNATIVE INTERVENTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
OUTCOMES ,[object Object],[object Object],[object Object]
IDENTIFYING,MEASUREMENT AND VALUATION OF COSTS ,[object Object],[object Object]
IDENTIFYING RELEVANT COSTS ,[object Object],[object Object]
COSTS ,[object Object],[object Object],[object Object]
Costs can be described in many ways ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
MEASURING COSTS ,[object Object],[object Object]
VALUING COSTS ,[object Object]
SENSITIVITY ANALYSIS ,[object Object],[object Object]
DISCOUNTING ,[object Object],[object Object]
JOURNALS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
REFERENCES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ASSIGNMENT ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Recommandé

Causality assessment scale
Causality assessment scaleCausality assessment scale
Causality assessment scaledrarunsingh4
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 
SURROGATE ENDPOINTS in Clinical Research.pptx
SURROGATE ENDPOINTS in Clinical Research.pptxSURROGATE ENDPOINTS in Clinical Research.pptx
SURROGATE ENDPOINTS in Clinical Research.pptxSiro Clinical Research Institute
 
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
PharmacovigilanceGaurav kumar
 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoringReyaz Bhat
 
Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURAzierta
 
ADVERSE DRUG REACTION
ADVERSE DRUG REACTIONADVERSE DRUG REACTION
ADVERSE DRUG REACTIONShubhamChaudhary230
 

Recommandé

Causality assessment scale
Causality assessment scaleCausality assessment scale
Causality assessment scaledrarunsingh4
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillencebdvfgbdhg
 
SURROGATE ENDPOINTS in Clinical Research.pptx
SURROGATE ENDPOINTS in Clinical Research.pptxSURROGATE ENDPOINTS in Clinical Research.pptx
SURROGATE ENDPOINTS in Clinical Research.pptxSiro Clinical Research Institute
 
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
PharmacovigilanceGaurav kumar
 
Prescription event monitoring
Prescription event monitoringPrescription event monitoring
Prescription event monitoringReyaz Bhat
 
Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURAzierta
 
ADVERSE DRUG REACTION
ADVERSE DRUG REACTIONADVERSE DRUG REACTION
ADVERSE DRUG REACTIONShubhamChaudhary230
 
Spontaneous reporting
Spontaneous reportingSpontaneous reporting
Spontaneous reportingShahiBushraKhan1
 
Fixed-effect and random-effects models in meta-analysis
Fixed-effect and random-effects models in meta-analysisFixed-effect and random-effects models in meta-analysis
Fixed-effect and random-effects models in meta-analysisRizwan S A
 
Pharmacoeconomics ii
Pharmacoeconomics iiPharmacoeconomics ii
Pharmacoeconomics iiAakankshaPriya1
 
Pharmacovigilance and Drug safety
Pharmacovigilance and Drug safety Pharmacovigilance and Drug safety
Pharmacovigilance and Drug safety ClinosolIndia
 
Chapter 1[1]
Chapter 1[1]Chapter 1[1]
Chapter 1[1]Kym Anne Surmion II
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomicspreetidharapur
 
Overcoming the Challenges of Benefit Risk Assessment for Established Products
Overcoming the Challenges of Benefit Risk Assessment for Established ProductsOvercoming the Challenges of Benefit Risk Assessment for Established Products
Overcoming the Challenges of Benefit Risk Assessment for Established ProductsSGS
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDYSuvarta Maru
 
Pharmacovigilance Planning
Pharmacovigilance PlanningPharmacovigilance Planning
Pharmacovigilance PlanningClinosolIndia
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
PharmacoeconomicsDr VARUN RAGHAVAN
 
History and development of pharmacovigilance.pptx
History and development of pharmacovigilance.pptxHistory and development of pharmacovigilance.pptx
History and development of pharmacovigilance.pptxReshmaManeDeshmukh
 
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...László Árvai
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziPharmaceutical Compliance Inspection unit, Crown College of Canada
 
Study of Vaccine safety
Study of Vaccine safetyStudy of Vaccine safety
Study of Vaccine safetySumitraj Pagare
 
Presentation CIOMS VIII
Presentation CIOMS VIIIPresentation CIOMS VIII
Presentation CIOMS VIIIFrancois MAIGNEN
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
PharmacoeconomicsZainab&Sons
 
Spontaneous Reporting System
Spontaneous Reporting SystemSpontaneous Reporting System
Spontaneous Reporting SystemJasdeep singh brar
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
PharmacovigilanceFariha Shikoh
 
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLS
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSDrug Safety & Pharmacovigilance - Introduction - Katalyst HLS
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsSatish Veerla
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
PharmacoeconomicsSanghmitra Priyadarshini
 
Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSAPharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSAStevce Acevski
 

Contenu connexe

Tendances

Fixed-effect and random-effects models in meta-analysis
Fixed-effect and random-effects models in meta-analysisFixed-effect and random-effects models in meta-analysis
Fixed-effect and random-effects models in meta-analysisRizwan S A
 
Pharmacovigilance and Drug safety
Pharmacovigilance and Drug safety Pharmacovigilance and Drug safety
Pharmacovigilance and Drug safety ClinosolIndia
 
Overcoming the Challenges of Benefit Risk Assessment for Established Products
Overcoming the Challenges of Benefit Risk Assessment for Established ProductsOvercoming the Challenges of Benefit Risk Assessment for Established Products
Overcoming the Challenges of Benefit Risk Assessment for Established ProductsSGS
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDYSuvarta Maru
 
Pharmacovigilance Planning
Pharmacovigilance PlanningPharmacovigilance Planning
Pharmacovigilance PlanningClinosolIndia
 
History and development of pharmacovigilance.pptx
History and development of pharmacovigilance.pptxHistory and development of pharmacovigilance.pptx
History and development of pharmacovigilance.pptxReshmaManeDeshmukh
 
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...László Árvai
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
PharmacoeconomicsZainab&Sons
 
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLS
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSDrug Safety & Pharmacovigilance - Introduction - Katalyst HLS
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsSatish Veerla
 

Tendances (20)

Spontaneous reporting
Spontaneous reportingSpontaneous reporting
Spontaneous reporting
 
Fixed-effect and random-effects models in meta-analysis
Fixed-effect and random-effects models in meta-analysisFixed-effect and random-effects models in meta-analysis
Fixed-effect and random-effects models in meta-analysis
 
Pharmacoeconomics ii
Pharmacoeconomics iiPharmacoeconomics ii
Pharmacoeconomics ii
 
Pharmacovigilance and Drug safety
Pharmacovigilance and Drug safety Pharmacovigilance and Drug safety
Pharmacovigilance and Drug safety
 
Chapter 1[1]
Chapter 1[1]Chapter 1[1]
Chapter 1[1]
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Overcoming the Challenges of Benefit Risk Assessment for Established Products
Overcoming the Challenges of Benefit Risk Assessment for Established ProductsOvercoming the Challenges of Benefit Risk Assessment for Established Products
Overcoming the Challenges of Benefit Risk Assessment for Established Products
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDY
 
Pharmacovigilance Planning
Pharmacovigilance PlanningPharmacovigilance Planning
Pharmacovigilance Planning
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
History and development of pharmacovigilance.pptx
History and development of pharmacovigilance.pptxHistory and development of pharmacovigilance.pptx
History and development of pharmacovigilance.pptx
 
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
General principles of Periodic Safety Update Reports(PSUR)Psur by Julia Appel...
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
 
Study of Vaccine safety
Study of Vaccine safetyStudy of Vaccine safety
Study of Vaccine safety
 
Presentation CIOMS VIII
Presentation CIOMS VIIIPresentation CIOMS VIII
Presentation CIOMS VIII
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Spontaneous Reporting System
Spontaneous Reporting SystemSpontaneous Reporting System
Spontaneous Reporting System
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLS
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSDrug Safety & Pharmacovigilance - Introduction - Katalyst HLS
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLS
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
 

En vedette

Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSAPharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSAStevce Acevski
 
Intro to pharmacoeconomics
Intro to pharmacoeconomicsIntro to pharmacoeconomics
Intro to pharmacoeconomicssamthamby79
 
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Evaluating Health Technology Assessment Reports and New Assessment Techniques...Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Evaluating Health Technology Assessment Reports and New Assessment Techniques...bpstat
 
Hol webinar summary
Hol webinar summaryHol webinar summary
Hol webinar summaryCameron Tew
 
Pharmacoeconomic moh program 1
Pharmacoeconomic moh program 1Pharmacoeconomic moh program 1
Pharmacoeconomic moh program 1Noura Aljohani
 
Pharmacoeconomic Assessment through Market Approval and Beyond
Pharmacoeconomic Assessment through Market Approval and BeyondPharmacoeconomic Assessment through Market Approval and Beyond
Pharmacoeconomic Assessment through Market Approval and BeyondMedpace
 
Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)Arlen Meyers, MD, MBA
 
Josh feldstein hopr (presentation)
Josh feldstein hopr (presentation)Josh feldstein hopr (presentation)
Josh feldstein hopr (presentation)jonblanck
 
The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...Sax Institute
 
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016ipposi
 
Pharmacoeconomics by harsh
Pharmacoeconomics by harshPharmacoeconomics by harsh
Pharmacoeconomics by harshHarsh Yadav
 
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmDStudies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmDDr.Sohel Memon
 
Pharmacoeconomics & drug compliance
Pharmacoeconomics & drug compliance Pharmacoeconomics & drug compliance
Pharmacoeconomics & drug compliance Naser Tadvi
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
PharmacoepidemiologyDivjyot Kaur
 
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig UniversityHistology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig Universityguestd708a83
 
Pharmacoeconomics
Pharmacoeconomics Pharmacoeconomics
Pharmacoeconomics CLARAsteven7
 

En vedette (20)

Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Pharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSAPharmacoeconomic aspects for treatment of MRSA
Pharmacoeconomic aspects for treatment of MRSA
 
Pharmaconomics
PharmaconomicsPharmaconomics
Pharmaconomics
 
Pharmacoeconomics seminar
Pharmacoeconomics seminarPharmacoeconomics seminar
Pharmacoeconomics seminar
 
Intro to pharmacoeconomics
Intro to pharmacoeconomicsIntro to pharmacoeconomics
Intro to pharmacoeconomics
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Evaluating Health Technology Assessment Reports and New Assessment Techniques...Evaluating Health Technology Assessment Reports and New Assessment Techniques...
Evaluating Health Technology Assessment Reports and New Assessment Techniques...
 
Hol webinar summary
Hol webinar summaryHol webinar summary
Hol webinar summary
 
Pharmacoeconomic moh program 1
Pharmacoeconomic moh program 1Pharmacoeconomic moh program 1
Pharmacoeconomic moh program 1
 
Pharmacoeconomic Assessment through Market Approval and Beyond
Pharmacoeconomic Assessment through Market Approval and BeyondPharmacoeconomic Assessment through Market Approval and Beyond
Pharmacoeconomic Assessment through Market Approval and Beyond
 
Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)Basics of pharmacoeconomics_and_outcomes_research (2)
Basics of pharmacoeconomics_and_outcomes_research (2)
 
Josh feldstein hopr (presentation)
Josh feldstein hopr (presentation)Josh feldstein hopr (presentation)
Josh feldstein hopr (presentation)
 
The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...
 
HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016HTA training - Dr Roisin Adams - March 27th 2016
HTA training - Dr Roisin Adams - March 27th 2016
 
Pharmacoeconomics by harsh
Pharmacoeconomics by harshPharmacoeconomics by harsh
Pharmacoeconomics by harsh
 
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmDStudies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
 
Pharmacoeconomics & drug compliance
Pharmacoeconomics & drug compliance Pharmacoeconomics & drug compliance
Pharmacoeconomics & drug compliance
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig UniversityHistology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
Histology Practical Slides For CLinicaL Pharmacy ☮ Zagazig University
 
Pharmacoeconomics
Pharmacoeconomics Pharmacoeconomics
Pharmacoeconomics
 

Similaire à Pharmacoeconomics1

Outcomes, health economics and pharmacoeconomics
Outcomes, health economics and pharmacoeconomicsOutcomes, health economics and pharmacoeconomics
Outcomes, health economics and pharmacoeconomicsDureshahwar khan
 
Pharmacoeconomics pptx
Pharmacoeconomics pptxPharmacoeconomics pptx
Pharmacoeconomics pptxVishwasATL
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
PharmacoeconomicsIjeh Cyril
 
Pharmacoeconomics1
Pharmacoeconomics1Pharmacoeconomics1
Pharmacoeconomics1jinender16
 
Pharmacoeconomics.ppt
Pharmacoeconomics.pptPharmacoeconomics.ppt
Pharmacoeconomics.pptPabitra Thapa
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
PharmacoeconomicsZainab&Sons
 
Seminar pharmacoeconomics
Seminar pharmacoeconomicsSeminar pharmacoeconomics
Seminar pharmacoeconomicsSameerKhasbage
 
Pharmacoeconomics ppt.
Pharmacoeconomics ppt.Pharmacoeconomics ppt.
Pharmacoeconomics ppt.shahvijita
 
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018Dr Roohana Hasan
 
Pharmacoeconomis
PharmacoeconomisPharmacoeconomis
PharmacoeconomisAanchal46
 
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and ...Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and ...Aasritha William
 
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...home
 
Pharmacoeconomics & pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioologyPharmacoeconomics & pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioologyDivya singh
 
pharmacoeconomic_models.pdf
pharmacoeconomic_models.pdfpharmacoeconomic_models.pdf
pharmacoeconomic_models.pdfKRIMSExamination
 

Similaire à Pharmacoeconomics1 (20)

Outcomes, health economics and pharmacoeconomics
Outcomes, health economics and pharmacoeconomicsOutcomes, health economics and pharmacoeconomics
Outcomes, health economics and pharmacoeconomics
 
Pharmacoeconomics pptx
Pharmacoeconomics pptxPharmacoeconomics pptx
Pharmacoeconomics pptx
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Pharmacoeconomics1
Pharmacoeconomics1Pharmacoeconomics1
Pharmacoeconomics1
 
Pharmaconomics
PharmaconomicsPharmaconomics
Pharmaconomics
 
Pharmacoeconomics.ppt
Pharmacoeconomics.pptPharmacoeconomics.ppt
Pharmacoeconomics.ppt
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Seminar pharmacoeconomics
Seminar pharmacoeconomicsSeminar pharmacoeconomics
Seminar pharmacoeconomics
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Pharmacoeconomics ppt.
Pharmacoeconomics ppt.Pharmacoeconomics ppt.
Pharmacoeconomics ppt.
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018Pharmacoeconomics 22 feb 2018
Pharmacoeconomics 22 feb 2018
 
PHARMACOECONOMICS.pptx
PHARMACOECONOMICS.pptxPHARMACOECONOMICS.pptx
PHARMACOECONOMICS.pptx
 
Pharmacoeconomis
PharmacoeconomisPharmacoeconomis
Pharmacoeconomis
 
Pharmacoeconomis
PharmacoeconomisPharmacoeconomis
Pharmacoeconomis
 
Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and ...Principles of Pharmacoeconomics and ...
Principles of Pharmacoeconomics and ...
 
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
Is complementary and alternative medicine (CAM) cost-effective? a systematic ...
 
Pharmacoeconomics & pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioologyPharmacoeconomics & pharmacoepidemioology
Pharmacoeconomics & pharmacoepidemioology
 
pharmacoeconomic_models.pdf
pharmacoeconomic_models.pdfpharmacoeconomic_models.pdf
pharmacoeconomic_models.pdf
 

Plus de jinender16

Seminar Jinender
Seminar JinenderSeminar Jinender
Seminar Jinenderjinender16
 
Patient Attitude Towards Gifts To Physicians
Patient Attitude Towards Gifts To PhysiciansPatient Attitude Towards Gifts To Physicians
Patient Attitude Towards Gifts To Physiciansjinender16
 
Pseudoephedrine
PseudoephedrinePseudoephedrine
Pseudoephedrinejinender16
 
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical IndustryDirect To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industryjinender16
 
Poster Jinender
Poster JinenderPoster Jinender
Poster Jinenderjinender16
 

Plus de jinender16 (9)

ISPOR
ISPORISPOR
ISPOR
 
Poster
PosterPoster
Poster
 
Seminar Jinender
Seminar JinenderSeminar Jinender
Seminar Jinender
 
APha Poster
APha PosterAPha Poster
APha Poster
 
Patient Attitude Towards Gifts To Physicians
Patient Attitude Towards Gifts To PhysiciansPatient Attitude Towards Gifts To Physicians
Patient Attitude Towards Gifts To Physicians
 
Singapore
SingaporeSingapore
Singapore
 
Pseudoephedrine
PseudoephedrinePseudoephedrine
Pseudoephedrine
 
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical IndustryDirect To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
Direct To Consumer Advertising Of Prescription Drugs Pharmaceutical Industry
 
Poster Jinender
Poster JinenderPoster Jinender
Poster Jinender
 

Pharmacoeconomics1

  • 1.
  • 2.
  • 3.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.